John H. Ward,
MD
Languages Spoken: English
John H. Ward, MD, is the Margaret A. Amundsen Endowed Professor of Medicine. He is a member of the Oncology Division in the Department of Internal Medicine at the University of Utah School of Medicine. Ward is an investigator at the Huntsman Cancer Institute. He served as Chief of the Oncology Division from 1998-2012. He is a past President of the Medical Staff of the University of Utah Hospital and Clinics. He served as the Huntsman Cancer Institute Interim Senior Director of Clinical Affairs and the HCI Interim Physician in Chief from 2019-2021.
Ward sees patients with a variety of malignant diseases, with an emphasis on breast cancer. Ward represents Huntsman Cancer Institute on the breast cancer treatment guidelines panel of the National Comprehensive Cancer Network. He also provides outreach Hematology/Oncology services for Huntsman Cancer Institute in Jackson Hole, Wyoming.
A graduate of the University of Utah School of Medicine, Ward completed an internal medicine residency at Duke University where he received the Haskel Schiff award as the outstanding internal medicine resident. He completed a fellowship in hematology/oncology at the University of Utah School of Medicine and has been on the faculty since 1982. Ward is board certified in internal medicine, medical oncology, and hematology. He has received numerous accolades for his teaching excellence, including the 2002 James L. Parkin, MD, award for outstanding clinical teaching at the University of Utah School of Medicine. He received the Huntsman Cancer Foundation Humanitarian Award in 2010. In 2017, he received the Outstanding Clinical Leadership Award of the University of Utah Health Regional Network. In 2021, he was recognized with the Department of Internal Medicine's Chair Award for Lifetime Achievement.
Clinical Locations
Clinic 3A, Center for Breast Health
801-213-4269
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.6/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
July 31, 2021
HUNTSMAN CANCER CENTER
Dr.Ward is the finest!!!!
UofU Patient
July 30, 2021
HUNTSMAN CANCER CENTER
Very fine and professional PA
UofU Patient
July 12, 2021
HUNTSMAN CANCER CENTER
Dr. Ward is always so wonderful. I'm lucky he's my doctor.
UofU Patient
June 14, 2021
HUNTSMAN CANCER CENTER
again, the best!
UofU Patient
June 05, 2021
HUNTSMAN CANCER CENTER
Rosie and Dr. Ward are both exceptional!!!!
UofU Patient
June 04, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
May 31, 2021
HUNTSMAN CANCER CENTER
I wish all people had the kind of care I receive
UofU Patient
May 29, 2021
HUNTSMAN CANCER CENTER
Dr. Ward is always kind and a true professional.
UofU Patient
May 28, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
May 28, 2021
HUNTSMAN CANCER CENTER
Dr Ward is so kind and still be direct and honest giving me all the information that I need to make a good decision about my treatment
UofU Patient
May 23, 2021
HUNTSMAN CANCER CENTER
I felt like I was valued and cared about!
UofU Patient
May 23, 2021
HUNTSMAN CANCER CENTER
As always wonderful experience. Dr. Ward and his stall are amazing.
UofU Patient
May 22, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
May 11, 2021
HUNTSMAN CANCER CENTER
Because of my bad reaction to my recent medication decision, we discussed and decided on the new course of acting.
UofU Patient
May 03, 2021
HUNTSMAN CANCER CENTER
Dr. Ward, Rosie and nurses are exceptional!!!!
UofU Patient
May 01, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
April 30, 2021
HUNTSMAN CANCER CENTER
Dr. Ward is the best
UofU Patient
April 10, 2021
HUNTSMAN CANCER CENTER
Dr. Ward is amazing. He's kind, thoughtful and respectful always.
UofU Patient
April 02, 2021
HUNTSMAN CANCER CENTER
my doctor is very patient and a great listener
UofU Patient
March 31, 2021
HUNTSMAN CANCER CENTER
They listened and understood my personal needs, and understood what "I" needed.
UofU Patient
March 27, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
March 20, 2021
HUNTSMAN CANCER CENTER
Dr. Ward is wonderful!
UofU Patient
March 06, 2021
HUNTSMAN CANCER CENTER
I love, love this provider. Heart of Gold!
UofU Patient
March 03, 2021
HUNTSMAN CANCER CENTER
Pleased and satisfied with all.
UofU Patient
February 26, 2021
HUNTSMAN CANCER CENTER
Dr. Ward is extraordinary
UofU Patient
February 15, 2021
HUNTSMAN CANCER CENTER
Rosie and Dr. Ward are an incredible team. I feel like I am in the best hands with both of them. They are extremely compassionate, intelligent, caring, and put me completely at ease.
UofU Patient
February 07, 2021
HUNTSMAN CANCER CENTER
Rosie (NP) and Dr. Ward are exceptional! I have the best of care possible!!
UofU Patient
February 07, 2021
HUNTSMAN CANCER CENTER
Dr Ward , Pam and the entire staff are so kind, engaging and awesome!!
UofU Patient
February 05, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
February 05, 2021
HUNTSMAN CANCER CENTER
Dr. Ward is always very calm, patient and understanding. He listens and explains things very well.
UofU Patient
February 01, 2021
HUNTSMAN CANCER CENTER
My health concerns were described very thoroughly to myself and Son
UofU Patient
January 07, 2021
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
January 02, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
December 27, 2020
HUNTSMAN CANCER CENTER
I love Dr ward and his staff!'nn
UofU Patient
December 13, 2020
HUNTSMAN CANCER CENTER
She was awesome!
UofU Patient
December 13, 2020
HUNTSMAN CANCER CENTER
Discussion about medication was very helpful.
UofU Patient
December 05, 2020
HUNTSMAN CANCER CENTER
Dr. Ward is absolutely the finest!!!!!!
UofU Patient
December 05, 2020
HUNTSMAN CANCER CENTER
Very good. All have been thorough, thoughtful, knowledgeable and concerned.
UofU Patient
December 04, 2020
HUNTSMAN CANCER CENTER
Parking was a nightmare
UofU Patient
December 02, 2020
HUNTSMAN CANCER CENTER
I think Dr. John Ward is an excellent Oncologist who exemplifies professionalism and compassion. I am very grateful to be treated by him.
UofU Patient
November 27, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
November 22, 2020
HUNTSMAN CANCER CENTER
Very good considering my scary feelings about the return of my Metastatic Breast Carcinoma in my right lung! Hard for me to listen & understand!
UofU Patient
November 22, 2020
HUNTSMAN CANCER CENTER
care provider was very concerned about my issue
UofU Patient
November 21, 2020
HUNTSMAN CANCER CENTER
very concern about my well-being
UofU Patient
November 14, 2020
HUNTSMAN CANCER CENTER
Dr. Ward is exceptional! He is always very caring, very professional and very pleasant! He is the best!!!!
UofU Patient
November 09, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
November 06, 2020
HUNTSMAN CANCER CENTER
love everyone.
UofU Patient
October 23, 2020
HUNTSMAN CANCER CENTER
Dr. Ward is the finest....very calming, compassionate, professional and extremely knowledgeable.
UofU Patient
October 20, 2020
HUNTSMAN CANCER CENTER
Good
UofU Patient
October 18, 2020
HUNTSMAN CANCER CENTER
Good
John H. Ward, MD, is the Margaret A. Amundsen Endowed Professor of Medicine. He is a member of the Oncology Division in the Department of Internal Medicine at the University of Utah School of Medicine. Ward is an investigator at the Huntsman Cancer Institute. He served as Chief of the Oncology Division from 1998-2012. He is a past President of the Medical Staff of the University of Utah Hospital and Clinics. He served as the Huntsman Cancer Institute Interim Senior Director of Clinical Affairs and the HCI Interim Physician in Chief from 2019-2021.
Ward sees patients with a variety of malignant diseases, with an emphasis on breast cancer. Ward represents Huntsman Cancer Institute on the breast cancer treatment guidelines panel of the National Comprehensive Cancer Network. He also provides outreach Hematology/Oncology services for Huntsman Cancer Institute in Jackson Hole, Wyoming.
A graduate of the University of Utah School of Medicine, Ward completed an internal medicine residency at Duke University where he received the Haskel Schiff award as the outstanding internal medicine resident. He completed a fellowship in hematology/oncology at the University of Utah School of Medicine and has been on the faculty since 1982. Ward is board certified in internal medicine, medical oncology, and hematology. He has received numerous accolades for his teaching excellence, including the 2002 James L. Parkin, MD, award for outstanding clinical teaching at the University of Utah School of Medicine. He received the Huntsman Cancer Foundation Humanitarian Award in 2010. In 2017, he received the Outstanding Clinical Leadership Award of the University of Utah Health Regional Network. In 2021, he was recognized with the Department of Internal Medicine's Chair Award for Lifetime Achievement.
Academic Locations
307-739-6195
Huntsman Cancer Hospital
801-585-0255
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Education History
| Fellowship | University of Utah School of Medicine Hematology/Oncology Fellow |
| Residency | Duke University Medical Center Internal Medicine Resident |
| Internship | Duke University Medical Center Internal Medicine Intern |
| Professional Medical | University of Utah Hospital School of Medicine Medicine M.D. |
| Undergraduate | University of Utah B.S. |
Selected Publications - Journal Articles
Journal Article
- Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, JCO2003609.
- Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510.
- Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R (2021). NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw, 19(5), 484-493.
- Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG (2020). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist, 25(11), e1655-e1662.
- Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(4), 452-478.
- Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R (2019). NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw, 17(2), 118-126.
- Katz BJ, Ward JH, Digre KB, Creel DJ, Mamalis N (2003). Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol, 23(2), 132-5.
- Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW (1996). Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum, 39(2), 325-9.
- Mann H, Ward JH, Samlowski WE (1990). Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology, 176(1), 191-4.
Abstract
- Yousef Zakharia, Olivier Rixe, John Harris Ward, Joseph J Drabick, Montaser F Shaheen, Mohammed M Milhem, David Munn, Eugene Paul Kennedy, Nicholas N Vahanian, Charles J Link, Robert R McWilliams, University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA, GRU Cancer Center, Augusta, GA, Huntsman Cancer Inst Univ of Utah, Salt Lake City, UT, Penn State Hershey Medical Center, Hershey, PA, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, Georgia Cancer Center, Augusta University, Augusta, GA, NewLink Genetics Corporation, Ames, IA, Mayo Clinic, Rochester, MN (06/04/2018). Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.Presented at 2018 ASCO Annual meeting June 4, 2018. [Abstract]. J Clin Oncology, 36(suppl. abstr 9512).